ClinicalTrials.gg
RecruitingNCT07060950ALCINA 5Updated Nov 6, 2026

Analysis of Circulating Tumor Markers in Blood - ALCINA 5

An interventional study of Blood sampling C1 in Cancer and Lung Cancer, Non-Small Cell, sponsored by Institut du Cancer de Montpellier - Val d'Aurelle. Recruiting at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-06.

Sponsored by Institut du Cancer de Montpellier - Val d'Aurelle · Not applicable, Interventional, and Diagnostic

How we know

From the registry’s dates

  • Started Sep 2025; still recruiting 1 year 1 month later.
Updated Nov 6, 2026Now RecruitingSite recruiting status changed+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
620
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Study summary

The circulating tumoral biomarkers in the blood are the object of numerous researches for several decades. The potential clinical interests of these circulating biomarkers are diagnostic, prognostic, predictive of the efficiency of targeted therapies (according to the mutational profile of the cancer), and could allow the study of the mechanisms of resistance under process. In the multiplicity of these blood potential biomarkers joins a permanent evolution of the technological means used to detect them/to quantify, as well as to estimate their clinical utility.

Read the detailed description

The new major challenge in research focuses on the rapid evaluation of circulating biomarker candidates, which could replace or complement molecular analyses of tumor tissue obtained through biopsy (for example the search for somatic mutations of cancer) by a simple blood test (liquid biopsy). The other current important challenge is to have an idea of the interest to analyse the kinetics of blood markers, in particular in answer to a clinical "event", either through the chemotherapy, a biopsy and / or surgery. There is almost no data in the literature on this aspect. It is very likely that the liberation in the blood of the blood tumoral markers is strongly dependent on medical interventions on the tumour.

The study ALCINA 5 relies exactly on the principle of small cohorts based on the analysis of circulating tumour biomarkers obtained by blood sampling, with comparison - if necessary - with tumour material obtained by biopsy. Which cohort correspond each to a clinical situation and/or a technique of different implemented detection. In case of success, statistical hypotheses will be necessary for the implementation of wider studies (being then the object of a specific approval by competent authorities).

02

Conditions studied

  • Cancer
  • Lung Cancer, Non-Small Cell
03

In context

Neoplasms

10,838 studies on the registry are indexed under Neoplasms; 2,322 are open to participants now.

This study's planned enrollment of 620 is above the median of 60 across 7,716 interventional studies indexed under Neoplasms.

Browse Neoplasms studies →

Lead sponsor

Institut du Cancer de Montpellier - Val d'Aurelle is the lead sponsor of 142 studies on the registry; 46 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patient presenting an invasive tumoral pathology (proved or suspected), whatever is the location or the stage,
  2. 18 years old or higher ?
  3. Patient who has provided informed, written, and explicit consent,
  4. Patient affiliated with a French Social Protection System.

    In the case of a tumor :

  5. Tumor considered as accessible by biopsy,
  6. Normal hemostasis assessment (PT, , ),
  7. No anticoagulant or antiaggregant treatment for the biopsy.

Exclusion criteria

Exclusion Criteria:

  1. Pregnant woman and/or breast-feeding,
  2. Patient whose regular follow-up is impossible for psychological, family, social or geographical reasons,
  3. Private persons of freedom or under guardianship,
  4. Patient with a history of other invasive cancers within the 5 years preceding inclusion.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

05

Study design

Phase
Not applicable
Primary purpose
Diagnostic
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
620 participants (estimated)

Study arms

  • Other
    COHORT 1 - CURE

    Patients with histologically proven metastatic non-small cell lung carcinoma eligible for immunotherapy

    Biological: Blood sampling C1

Interventions

  • BiologicalBlood sampling C1

    Blood samples will be collected at four key time points : * baseline (T1), * first scan assessment (T2), * second scan assessment (T3), * and progression (T4).

06

What researchers measure

Primary outcomes

  1. All Cohorts : Study of the feasibility of detecting and/or analysing blood or tissue tumour biomarkers.

    Success rate of the detection technique used (the criterion will be detailed according to the biomarker evaluated, in each of the cohorts)

    Time frame: 10 years

Secondary outcomes

  1. COHORT 1 - CURE : to define a liquid biopsy signature for predicting therapeutic response from samples taken before initiation of immunotherapy (T1).

    CTCs-PD-L1+/-, ctDNA, circulating proteins (CPs) and circulating immune cells (CICs) will be measured in accordance with the definitions established in T1.

    Time frame: 4 years

07

Study locations

1 of 1 sites recruiting
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2025 (actual). Primary completion is estimated for Jul 2030, 58 months after the start.

Of 1,993 non-industry interventional studies with no phase under Neoplasms, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 52. This study's planned 58 months is above that.

Counting every sponsor, half of 2,068 studies reached it within 29 months; a quarter within 13 and three quarters within 52.

Neoplasms covers many different conditions, not one, so the studies compared here vary widely. Read these figures as a rough guide.

Start moved once since we started tracking on Sep 25, 2026: Oct 2025 → Sep 2025, on Nov 6, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jul 2, 2025
First posted
Jul 11, 2025
StartActual
Sep 26, 2025was Oct 2025
Primary completionEst.
Jul 2030
CompletionEst.
Jul 2035
Last update
Nov 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Nov 6, 2026
Sites
Centre Regional de Lutte Contre le Cancer - Centre Val d'Aurelle is now Recruiting
Nov 6, 2026
Start date
Oct 2025→Sep 26, 2025 (actual)
Nov 6, 2026
Show all 1 update
  1. Nov 6, 2026
    Not yet recruiting→Recruiting
    Centre Regional de Lutte Contre le Cancer - Centre Val d'Aurelle is now Recruiting
    Start date Oct 2025→Sep 26, 2025 (now actual)
    + 2 other changes: verification date and oversight details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07060950
Responsible party
Sponsor
First posted
Jul 11, 2025
Start date
Sep 26, 2025
Primary completion
Jul 2030 (estimated)
Completion
Jul 2035 (estimated)
Last update
Nov 6, 2026

Study contacts

Emmanuelle TEXIER
Contact
emmanuelle.texier@icm.unicancer.fr
467613102 ext. +33

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion